Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 317

1.

Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy.

Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G.

Clin Microbiol Rev. 2020 Feb 26;33(2). pii: e00046-19. doi: 10.1128/CMR.00046-19. Print 2020 Mar 18. Review.

PMID:
32102898
2.

Will we need novel combinations to cure HBV infection?

Dusheiko G.

Liver Int. 2020 Feb;40 Suppl 1:35-42. doi: 10.1111/liv.14371. Review.

PMID:
32077595
3.

Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1.

Spaan M, Carey I, Bruce M, Shang D, Horner M, Dusheiko G, Agarwal K.

J Hepatol. 2020 Jan 22. pii: S0168-8278(20)30023-4. doi: 10.1016/j.jhep.2019.12.028. [Epub ahead of print]

PMID:
31981726
4.

Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B.

Lok AS, Zoulim F, Dusheiko G, Chan HLY, Buti M, Ghany MG, Gaggar A, Yang JC, Wu G, Flaherty JF, Subramanian GM, Locarnini S, Marcellin P.

Hepatol Commun. 2019 Oct 10;4(1):8-20. doi: 10.1002/hep4.1436. eCollection 2020 Jan.

5.

Reply to: "Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action".

Childs K, Cannon M, Davis C, Thompson EC, Dusheiko G, Agarwal K.

J Hepatol. 2020 Mar;72(3):585-586. doi: 10.1016/j.jhep.2019.11.010. Epub 2019 Dec 20. No abstract available.

PMID:
31870568
6.

Hepatitis B in sub-Saharan Africa-How many patients need therapy?

Sonderup MW, Dusheiko G, Desalegn H, Lemoine M, Tzeuton C, Taylor-Robinson SD, Spearman CW.

J Viral Hepat. 2019 Dec 4. doi: 10.1111/jvh.13247. [Epub ahead of print] Review.

PMID:
31800145
7.

Pre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy.

Carey I, Gersch J, Wang B, Moigboi C, Kuhns M, Cloherty G, Dusheiko G, Agarwal K.

Hepatology. 2019 Nov 7. doi: 10.1002/hep.31026. [Epub ahead of print]

PMID:
31701544
8.

Hepatitis C.

Spearman CW, Dusheiko GM, Hellard M, Sonderup M.

Lancet. 2019 Oct 19;394(10207):1451-1466. doi: 10.1016/S0140-6736(19)32320-7. Review.

PMID:
31631857
9.

Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C.

Childs K, Davis C, Cannon M, Montague S, Filipe A, Tong L, Simmonds P, Smith D, Thomson EC, Dusheiko G, Agarwal K.

J Hepatol. 2019 Dec;71(6):1099-1105. doi: 10.1016/j.jhep.2019.07.025. Epub 2019 Aug 7.

10.

Antiviral treatment for hepatitis C: rebalancing cost, affordability, and availability.

Dusheiko G, Gore C.

Lancet Glob Health. 2019 Sep;7(9):e1150-e1151. doi: 10.1016/S2214-109X(19)30313-4. Epub 2019 Jul 27. No abstract available.

11.

An appraisal of the WHO hepatitis B treatment guidelines applicability to Africans.

Dusheiko G, Lemoine M.

J Hepatol. 2019 Jun;70(6):1046-1048. doi: 10.1016/j.jhep.2019.03.009. Epub 2019 Mar 28. No abstract available.

12.

Hepatitis B virus infection in children and adolescents.

Indolfi G, Easterbrook P, Dusheiko G, Siberry G, Chang MH, Thorne C, Bulterys M, Chan PL, El-Sayed MH, Giaquinto C, Jonas MM, Meyers T, Walsh N, Wirth S, Penazzato M.

Lancet Gastroenterol Hepatol. 2019 Jun;4(6):466-476. doi: 10.1016/S2468-1253(19)30042-1. Epub 2019 Apr 11. Review.

PMID:
30982722
13.

Hepatitis C virus infection in children and adolescents.

Indolfi G, Easterbrook P, Dusheiko G, El-Sayed MH, Jonas MM, Thorne C, Bulterys M, Siberry G, Walsh N, Chang MH, Meyers T, Giaquinto C, Wirth S, Chan PL, Penazzato M.

Lancet Gastroenterol Hepatol. 2019 Jun;4(6):477-487. doi: 10.1016/S2468-1253(19)30046-9. Epub 2019 Apr 11. Review.

PMID:
30982721
14.

Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission.

Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, Hamid S, Hellard ME, Hou J, Howell J, Jia J, Kravchenko N, Lazarus JV, Lemoine M, Lesi OA, Maistat L, McMahon BJ, Razavi H, Roberts T, Simmons B, Sonderup MW, Spearman CW, Taylor BE, Thomas DL, Waked I, Ward JW, Wiktor SZ; Lancet Gastroenterology & Hepatology Commissioners.

Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184. doi: 10.1016/S2468-1253(18)30270-X. Review. Erratum in: Lancet Gastroenterol Hepatol. 2019 May;4(5):e4.

15.

Hepatitis B Surface Antigen Loss: Too Little, Too Late and the Challenge for the Future.

Dusheiko G, Wang B.

Gastroenterology. 2019 Feb;156(3):548-551. doi: 10.1053/j.gastro.2019.01.015. Epub 2019 Jan 11. No abstract available.

PMID:
30641057
16.

Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B.

Nguyen MH, Burak Ozbay A, Liou I, Meyer N, Gordon SC, Dusheiko G, Lim JK.

J Hepatol. 2019 Jan;70(1):24-32. doi: 10.1016/j.jhep.2018.09.021. Epub 2018 Oct 1.

17.

Current and future directions for the management of hepatitis B.

Dusheiko G.

S Afr Med J. 2018 Aug 8;108(8b):22-30. doi: 10.7196/SAMJ.2018.v108i8b.13497. Review.

PMID:
30182909
18.

Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B.

Nguyen MH, Lim JK, Burak Ozbay A, Fraysse J, Liou I, Meyer N, Dusheiko G, Gordon SC.

Hepatology. 2019 Mar;69(3):959-973. doi: 10.1002/hep.30246. Epub 2019 Feb 11.

19.

Predicting treatment eligibility for hepatitis B in low income regions: Can treatment scores without HBV DNA testing serve the purpose?

McMahon BJ, Dusheiko G.

J Hepatol. 2018 Oct;69(4):765-766. doi: 10.1016/j.jhep.2018.06.002. Epub 2018 Jul 11. No abstract available.

PMID:
30007507
20.

Hepatitis B virus infection.

Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL.

Nat Rev Dis Primers. 2018 Jun 7;4:18035. doi: 10.1038/nrdp.2018.35. Review.

PMID:
29877316
21.

Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults.

Mazzarelli C, Considine A, Childs K, Carey I, Manini MA, Suddle A, Dusheiko G, Agarwal K, Cannon MD.

J Am Geriatr Soc. 2018 Jul;66(7):1339-1345. doi: 10.1111/jgs.15392. Epub 2018 May 25.

PMID:
29799112
22.

Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B.

Carey I, Byrne R, Childs K, Horner M, Bruce M, Wang B, Dusheiko G, Agarwal K.

J Viral Hepat. 2018 Oct;25(10):1139-1150. doi: 10.1111/jvh.12916. Epub 2018 May 11.

PMID:
29660209
23.

Delineating the global challenges of hepatitis B virus infection.

Dusheiko G, Agarwal K.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):372-373. doi: 10.1016/S2468-1253(18)30093-1. Epub 2018 Mar 27. No abstract available.

PMID:
29599077
24.

Authors' reply.

Spearman CW, Sonderup MW, Dusheiko G; authors.

Lancet Gastroenterol Hepatol. 2018 Apr;3(4):224-225. doi: 10.1016/S2468-1253(18)30048-7. Epub 2018 Mar 7. No abstract available.

PMID:
29533194
25.

HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.

Wang B, Carey I, Bruce M, Montague S, Dusheiko G, Agarwal K.

J Viral Hepat. 2018 Aug;25(8):886-893. doi: 10.1111/jvh.12889. Epub 2018 Apr 2.

PMID:
29532589
26.

A Shift in Thinking to Reduce Mother-to-Infant Transmission of Hepatitis B.

Dusheiko G.

N Engl J Med. 2018 Mar 8;378(10):952-953. doi: 10.1056/NEJMe1801662. No abstract available.

PMID:
29514035
27.

Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6.

Asselah T, Hassanein T, Waked I, Mansouri A, Dusheiko G, Gane E.

J Hepatol. 2018 Apr;68(4):814-826. doi: 10.1016/j.jhep.2017.11.037. Epub 2017 Dec 8. Review.

PMID:
29229584
28.

Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.

Fathi H, Clark A, Hill NR, Dusheiko G.

BMC Infect Dis. 2017 Nov 16;17(1):722. doi: 10.1186/s12879-017-2820-z. Review.

29.

Hepatitis C in sub-Saharan Africa: the current status and recommendations for achieving elimination by 2030.

Sonderup MW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, Dusheiko G, Gogela N, Lohouès-Kouacou MJ, Lam P, Lesi O, Mbaye PS, Musabeyezu E, Musau B, Ojo O, Rwegasha J, Scholz B, Shewaye AB, Tzeuton C, Kassianides C, Spearman CW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA).

Lancet Gastroenterol Hepatol. 2017 Dec;2(12):910-919. doi: 10.1016/S2468-1253(17)30249-2. Review.

PMID:
29132760
30.

Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets.

Spearman CW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, Dusheiko G, Gogela N, Kassianides C, Kew M, Lam P, Lesi O, Lohouès-Kouacou MJ, Mbaye PS, Musabeyezu E, Musau B, Ojo O, Rwegasha J, Scholz B, Shewaye AB, Tzeuton C, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA).

Lancet Gastroenterol Hepatol. 2017 Dec;2(12):900-909. doi: 10.1016/S2468-1253(17)30295-9. Review.

PMID:
29132759
31.

Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar.

Kim YA, Trinh S, Thura S, Kyi KP, Lee T, Sze S, Richards A, Aronsohn A, Wong GLH, Tanaka Y, Dusheiko G, Nguyen MH.

PLoS One. 2017 Aug 10;12(8):e0181603. doi: 10.1371/journal.pone.0181603. eCollection 2017.

32.

Hepatitis B cure: From discovery to regulatory approval.

Lok AS, Zoulim F, Dusheiko G, Ghany MG.

J Hepatol. 2017 Oct;67(4):847-861. doi: 10.1016/j.jhep.2017.05.008. Epub 2017 Aug 1. Review.

PMID:
28778687
33.

Hepatitis B cure: From discovery to regulatory approval.

Lok AS, Zoulim F, Dusheiko G, Ghany MG.

Hepatology. 2017 Oct;66(4):1296-1313. doi: 10.1002/hep.29323. Epub 2017 Aug 1.

34.

Hepatitis C in the EU: setting the terms for elimination.

Dusheiko G.

Lancet Gastroenterol Hepatol. 2017 May;2(5):314-315. doi: 10.1016/S2468-1253(17)30073-0. Epub 2017 Mar 15. No abstract available.

PMID:
28397690
35.

The impact of antiviral therapy for hepatitis C on the quality of life: a perspective.

Dusheiko G.

Liver Int. 2017 Jan;37 Suppl 1:7-12. doi: 10.1111/liv.13292. Review.

PMID:
28052638
36.

Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia.

Kim YA, Estevez J, Le A, Israelski D, Baatarkhuu O, Sarantuya T, Narantsetseg S, Nymadawa P, H Le R, Yuen MF, Dusheiko G, Rizzetto M, Nguyen MH.

BMJ Open Gastroenterol. 2016 Nov 10;3(1):e000119. eCollection 2016.

37.

Bringing to an end mother-to-child transmission of hepatitis B: A role for quantitative hepatitis B surface antigen?

Dusheiko G, Easterbrook P.

Hepatology. 2016 Nov;64(5):1408-1410. doi: 10.1002/hep.28732. Epub 2016 Aug 27. No abstract available.

PMID:
27452950
38.

Conceptual framework for outcomes research studies of hepatitis C: an analytical review.

Sbarigia U, Denee TR, Turner NG, Wan GJ, Morrison A, Kaufman AS, Rice G, Dusheiko GM.

Infect Drug Resist. 2016 May 27;9:101-17. doi: 10.2147/IDR.S99329. eCollection 2016. Review.

39.

HBsAg loss in chronic hepatitis B: pointers to the benefits of curative therapy.

Dusheiko G, Wang B, Carey I.

Hepatol Int. 2016 Sep;10(5):727-9. doi: 10.1007/s12072-016-9738-1. Epub 2016 May 31. No abstract available.

PMID:
27246696
40.

Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B.

Li H, Chen LY, Zhang NN, Li ST, Zeng B, Pavesi M, Amorós À, Mookerjee RP, Xia Q, Xue F, Ma X, Hua J, Sheng L, Qiu DK, Xie Q, Foster GR, Dusheiko G, Moreau R, Gines P, Arroyo V, Jalan R.

Sci Rep. 2016 May 5;6:25487. doi: 10.1038/srep25487.

41.

Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations.

Yuen MF, Ahn SH, Chen DS, Chen PJ, Dusheiko GM, Hou JL, Maddrey WC, Mizokami M, Seto WK, Zoulim F, Lai CL.

J Clin Gastroenterol. 2016 Apr;50(4):286-94. doi: 10.1097/MCG.0000000000000478. Review.

PMID:
26840752
42.

Pregnancy and liver disease.

Westbrook RH, Dusheiko G, Williamson C.

J Hepatol. 2016 Apr;64(4):933-45. doi: 10.1016/j.jhep.2015.11.030. Epub 2015 Nov 30. Review.

PMID:
26658682
43.

Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders.

Visvanathan K, Dusheiko G, Giles M, Wong ML, Phung N, Walker S, Le S, Lim SG, Gane E, Ngu M, Hardikar W, Cowie B, Bowden S, Strasser S, Levy M, Sasaduesz J.

Gut. 2016 Feb;65(2):340-50. doi: 10.1136/gutjnl-2015-310317. Epub 2015 Oct 15. Review.

PMID:
26475631
44.

Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.

Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S.

Gut. 2015 Nov;64(11):1824-33. doi: 10.1136/gutjnl-2015-310421. Review.

45.

Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.

Bermingham SL, Hughes R, Fenu E, Sawyer LM, Boxall E, T Kennedy P, Dusheiko G, Hill-Cawthorne G, Thomas H.

Value Health. 2015 Sep;18(6):800-9. doi: 10.1016/j.jval.2015.05.007. Epub 2015 Jul 27.

46.

Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C".

Pawlotsky JM, Aghemo A, Back D, Dusheiko G, Forns X, Puoti M, Sarrazin C; EASL Recommendations on Treatment of Hepatitis C 2015 panel.

J Hepatol. 2015 Dec;63(6):1535-6. doi: 10.1016/j.jhep.2015.09.004. Epub 2015 Sep 12. No abstract available.

PMID:
26375242
47.

IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders.

Calisti G, Tavares A, Macartney MJ, McCormick A, Labbett W, Jacobs M, Dusheiko G, Rosenberg WM, Haque T.

Springerplus. 2015 Jul 16;4:357. doi: 10.1186/s40064-015-1137-x. eCollection 2015.

48.

Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.

Kalafateli M, Dusheiko G, Manousou P.

J Gastrointestin Liver Dis. 2015 Jun;24(2):257-8. No abstract available.

49.

Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.

Stockdale AJ, Phillips RO, Beloukas A, Appiah LT, Chadwick D, Bhagani S, Bonnett L, Sarfo FS, Dusheiko G, Geretti AM; Hepatitis B Infection in Kumasi (HEPIK) Study Group.

Clin Infect Dis. 2015 Sep 15;61(6):883-91. doi: 10.1093/cid/civ421. Epub 2015 May 28.

PMID:
26021992
50.

Hepatitis C treatment and quality of life - You can't always get what you want, but you might get what you need.

Mehta G, Dusheiko G.

J Hepatol. 2015 Aug;63(2):300-2. doi: 10.1016/j.jhep.2015.05.004. Epub 2015 May 14. No abstract available.

Supplemental Content

Loading ...
Support Center